Abbott Can't Kick Investor Suit Over Depakote Marketing

Law360, San Francisco (June 5, 2013, 6:48 PM EDT) -- A federal judge on Wednesday refused to toss a shareholder derivative suit against Abbott Laboratories, finding the plaintiffs had adequately argued Abbott's directors knew the company was in trouble for marketing off-label uses for the anti-seizure drug Depakote but did nothing, costing the company $1.6 billion.

U.S. District Judge Virginia M. Kendall rejected Abbott's argument that the plaintiffs had failed to show Abbott continued the unlawful marketing campaign through 2008 or that its board of directors knew something was amiss. The fact that the U.S. Department...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.